[go: up one dir, main page]

PE30891A1 - Composiciones y metodos terapeuticos sinergicos - Google Patents

Composiciones y metodos terapeuticos sinergicos

Info

Publication number
PE30891A1
PE30891A1 PE1991185538A PE18553891A PE30891A1 PE 30891 A1 PE30891 A1 PE 30891A1 PE 1991185538 A PE1991185538 A PE 1991185538A PE 18553891 A PE18553891 A PE 18553891A PE 30891 A1 PE30891 A1 PE 30891A1
Authority
PE
Peru
Prior art keywords
methods
therapeutic compositions
synergic
synergic therapeutic
therapeutic
Prior art date
Application number
PE1991185538A
Other languages
English (en)
Inventor
Antohony Andrea Fossa
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24080550&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE30891(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of PE30891A1 publication Critical patent/PE30891A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

EL METODO CONSISTE EN ADMINISTRAR A UN MAMIFERO CANTIDADES DE POR LO MENOS DOS AGENTES TERAPEUTICOS SELECCIONADOS ENTRE EL GRUPO FORMADO POR: (a) A UN INHIBIDOR DE LA RENINA;(b) UN INHIBIDOR DE LAS ENZIMAS CONVERTIDORAS DE ANGIOTENSINA I Y (c) UN ANTAGONISTA DE LA ANGIOTENSINA II, DONDE LA CANTIDAD DE (a), (b Y (c) POR SI SOLOS ES INSUFICIENTE PARA CONSEGUIR EL EFECTO TERAPEUTICO, SIENDO EL EFECTO COMBINADO DE LAS CANTIDADES DE LOS AGENTES TERAPEUTICOS ADMINISTRADOS SUPERIOR A LA SUMA DE LOS AGENTES TERAPEUTICOS INDIVIDUALES ADMINISTRADOS.
PE1991185538A 1990-05-11 1991-05-10 Composiciones y metodos terapeuticos sinergicos PE30891A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52236090A 1990-05-11 1990-05-11

Publications (1)

Publication Number Publication Date
PE30891A1 true PE30891A1 (es) 1991-11-27

Family

ID=24080550

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1991185538A PE30891A1 (es) 1990-05-11 1991-05-10 Composiciones y metodos terapeuticos sinergicos

Country Status (33)

Country Link
US (2) US6900234B1 (es)
EP (1) EP0527879B1 (es)
JP (2) JPH0729938B2 (es)
KR (1) KR970005839B1 (es)
CN (7) CN101156949A (es)
AP (1) AP240A (es)
AT (1) ATE148632T1 (es)
AU (1) AU653724B2 (es)
BG (1) BG61831B1 (es)
BR (1) BR9106438A (es)
CA (1) CA2081564C (es)
DE (1) DE69124598T2 (es)
DK (1) DK0527879T3 (es)
EG (1) EG19648A (es)
ES (1) ES2097208T3 (es)
GR (1) GR3022997T3 (es)
GT (1) GT199100032A (es)
HU (1) HU227346B1 (es)
IE (1) IE911592A1 (es)
IL (1) IL98055A (es)
IS (1) IS2042B (es)
MA (1) MA22150A1 (es)
MY (1) MY114347A (es)
NO (1) NO924321L (es)
NZ (1) NZ238118A (es)
PE (1) PE30891A1 (es)
PT (1) PT97615B (es)
RO (1) RO115786B1 (es)
RU (1) RU2147875C1 (es)
TW (1) TW203553B (es)
WO (1) WO1991017771A1 (es)
YU (1) YU49094B (es)
ZA (1) ZA913539B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2097208T3 (es) * 1990-05-11 1997-04-01 Pfizer Composiciones y procedimientos terapeuticos y sinergicos.
EP0629408A1 (en) * 1993-06-16 1994-12-21 LABORATOIRES MERCK, SHARP & DOHME-CHIBRET Combination of angiotensin converting enzyme inhibitors and AII antagonists
DE4340437C1 (de) * 1993-11-27 1995-05-24 Karla Dr Lehmann Verwendung von Lithiumverbindungen zur Behandlung von Herzinsuffizienz einschließlich ihrer Folgeerkrankungen
KR19980703647A (ko) * 1995-04-07 1998-12-05 베르너발데크 베나제프릴 또는 베나제프릴라트 및 발사르탄을 함유하는조성물
CA2224451A1 (en) * 1995-06-30 1997-01-23 Merck & Co., Inc. Method of treating renal disease using an ace inhibitor and an aii antagonist
ES2175385T5 (es) * 1996-04-05 2006-06-01 Takeda Chemical Industries, Ltd. Combinacion farmaceutica que contiene un compuesto que tiene actividad antagonista de angiotensina ii y un compuesto que aumenta la sensibilidad a la insulina.
DE69712338T2 (de) * 1996-06-24 2002-11-07 Merck & Co., Inc. Zusammensetzung auf basis von enalapril und losartan
US6087386A (en) * 1996-06-24 2000-07-11 Merck & Co., Inc. Composition of enalapril and losartan
US6248724B1 (en) 1997-09-25 2001-06-19 University Of Florida Antisense oligonucleotide compositions targeted to angiotensin converting enzyme MRNA and methods of use
KR20010033473A (ko) * 1997-12-23 2001-04-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Ａｃｅ 저해제-ｍｍｐ 저해제의 병용 제제
US6087343A (en) * 1998-09-14 2000-07-11 University Of Florida Antisense oligonucleotides targeted to β-1 adrenoceptor and methods of use
US6387894B1 (en) * 1999-06-11 2002-05-14 Pfizer Inc. Use of CRF antagonists and renin-angiotensin system inhibitors
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US20060013852A1 (en) * 2002-06-28 2006-01-19 Prescott Margaret F Use of organic compounds
CN104383542B (zh) 2003-04-08 2017-09-26 普罗热尼奇制药公司 包含甲基纳曲酮的药物配方
US20040265238A1 (en) 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
EP1799199B1 (en) * 2004-10-08 2012-03-28 Novartis AG Use of renin inhibitors for the prevention or treatment of diastolic dysfunction or diastolic heart failure
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
CN101171010B (zh) * 2005-03-07 2014-09-17 芝加哥大学 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
CL2007002689A1 (es) 2006-09-18 2008-04-18 Vitae Pharmaceuticals Inc Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
PL2137191T3 (pl) 2007-03-29 2016-12-30 Antagoniści obwodowego receptora opioidowego i ich zastosowania
WO2008121352A2 (en) 2007-03-29 2008-10-09 Progenics Pharmaceuticals, Inc. Crystal forms of (r) -n-methylnaltrexone bromide and uses thereof
DK2139890T3 (da) 2007-03-29 2014-08-25 Wyeth Llc Perifere opioidreceptor-antagonister og anvendelser deraf
KR101581480B1 (ko) 2008-02-06 2015-12-30 프로제닉스 파머슈티컬스, 인코포레이티드 (ｒ),(ｒ)-2,2'-비스-메틸날트렉손의 제조법 및 용도
EP2278966B1 (en) 2008-03-21 2019-10-09 The University of Chicago Treatment with opioid antagonists and mtor inhibitors
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
AR077692A1 (es) 2009-08-06 2011-09-14 Vitae Pharmaceuticals Inc Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo
CN102423483A (zh) * 2011-11-24 2012-04-25 西北农林科技大学 一种复方雷米普利纳米乳抗高血压药物
CN114032273B (zh) * 2021-11-17 2024-02-02 山东省科学院生物研究所 一种多功能西洋参水解肽及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US324377A (en) * 1885-08-18 Roller-skate
US4046889A (en) * 1976-02-13 1977-09-06 E. R. Squibb & Sons, Inc. Azetidine-2-carboxylic acid derivatives
IL58849A (en) * 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
JPS5671074A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
US4749688A (en) 1986-06-20 1988-06-07 Schering Corporation Use of neutral metalloendopeptidase inhibitors in the treatment of hypertension
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
DE3633861A1 (de) * 1986-10-04 1988-04-07 Thomae Gmbh Dr K Neue imidazo-benzoxazinone, ihre herstellung und diese verbindungen enthaltende arzneimittel
US4814342A (en) 1986-10-31 1989-03-21 Pfizer Inc. Nor-statine and nor-cyclostatine polypeptides
US4895834A (en) * 1986-12-15 1990-01-23 Warner-Lambert Company Renin inhibitors III
US4874759A (en) * 1987-01-23 1989-10-17 Yoshitomi Pharmaceutical Industries, Ltd. 5-Hydroxyindole-3-carboxylic acid amide compounds, pharmaceutical compositions and use
US4962105A (en) 1987-10-19 1990-10-09 Ciba-Geigy Corporation Potentiation of antihypertensive effect of ace inhibitors
US5015651A (en) 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
US4880804A (en) * 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
CA1338238C (en) 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
IL91780A (en) 1988-10-04 1995-08-31 Abbott Lab History of the amine of the xenon-preventing xanine acid, the process for their preparation and the pharmaceutical preparations containing them
ES2097208T3 (es) * 1990-05-11 1997-04-01 Pfizer Composiciones y procedimientos terapeuticos y sinergicos.

Also Published As

Publication number Publication date
RU2147875C1 (ru) 2000-04-27
BG61831B1 (bg) 1998-07-31
RO115786B1 (ro) 2000-06-30
NZ238118A (en) 1997-06-24
CA2081564C (en) 1998-02-03
CN1824315A (zh) 2006-08-30
BG97068A (bg) 1993-12-24
IL98055A (en) 1996-10-31
CN1824315B (zh) 2011-01-12
WO1991017771A1 (en) 1991-11-28
IE911592A1 (en) 1991-11-20
JPH05505618A (ja) 1993-08-19
YU49094B (sh) 2003-12-31
CA2081564A1 (en) 1991-11-12
ATE148632T1 (de) 1997-02-15
KR970005839B1 (ko) 1997-04-21
ZA913539B (en) 1992-12-30
US6716875B1 (en) 2004-04-06
IL98055A0 (en) 1992-06-21
JPH0748280A (ja) 1995-02-21
DK0527879T3 (da) 1997-07-14
DE69124598T2 (de) 1997-05-28
EP0527879B1 (en) 1997-02-05
CN1915428A (zh) 2007-02-21
NO924321D0 (no) 1992-11-10
CN1879884A (zh) 2006-12-20
ES2097208T3 (es) 1997-04-01
US6900234B1 (en) 2005-05-31
BR9106438A (pt) 1993-05-18
CN101156949A (zh) 2008-04-09
HU227346B1 (en) 2011-04-28
MY114347A (en) 2002-10-31
AU7859191A (en) 1991-12-10
EP0527879A1 (en) 1993-02-24
HUT62804A (en) 1993-06-28
NO924321L (no) 1993-01-08
GR3022997T3 (en) 1997-07-30
MA22150A1 (fr) 1991-12-31
CN1307901A (zh) 2001-08-15
DE69124598D1 (de) 1997-03-20
AP240A (en) 1993-02-18
PT97615A (pt) 1992-03-31
GT199100032A (es) 1992-10-31
AP9100258A0 (en) 1991-07-31
CN1065140C (zh) 2001-05-02
JP2635291B2 (ja) 1997-07-30
CN1056426A (zh) 1991-11-27
HU9203522D0 (en) 1993-01-28
EG19648A (en) 1995-09-30
JPH0729938B2 (ja) 1995-04-05
TW203553B (es) 1993-04-11
HK1094148A1 (en) 2007-03-23
AU653724B2 (en) 1994-10-13
CN100358578C (zh) 2008-01-02
CN1502370A (zh) 2004-06-09
YU81991A (sh) 1994-06-24
PT97615B (pt) 1998-08-31
IS2042B (is) 2005-09-15
IS3703A7 (is) 1991-11-12

Similar Documents

Publication Publication Date Title
PE30891A1 (es) Composiciones y metodos terapeuticos sinergicos
CO4410317A1 (es) Combinacion y conjuntos farmaceuticos de un antagonista o- pioide y un inhibidor de recaptacion selectiva de serotoni- na, y el tratamiento de alcoholismo y dependencia alcoholica empleando los mismos.
ATE91233T1 (de) Antivirale pharmazeutische zusammensetzungen und ihrer verwendung.
ES2190472T3 (es) Parche transdermico para la administracion de 17-deacetil norgestimato, solo o en combinacion con un estrogeno.
AR001413A1 (es) Compuestos triciclicos de carbamato, utiles para la inhibición de la función de la proteina g y paratratamiento de enfermedades proliferativas.
CO5011115A1 (es) Compuestos y metodos quimioquina
ES2094721T3 (es) Analogos de la camptotecina solubles en agua.
FI952680A0 (fi) Injektoitavia taksaanijohdannaisiin pohjautuvia koostumuksia
EA199800357A1 (ru) Фармацевтические ангиостатические дипептидные композиции и способы их применения
ES2194835T3 (es) Agentes antitromboticos a base de tripeptidos.
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
MX9300141A (es) Compuestos de imidazol novedosos, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
ES2155093T3 (es) Nuevos inhibidores de la uridina fosforilasa (urdpasa) y de la dihidrouracil deshidrogenasa (dhudasa).
BG100829A (bg) Бензотиофен, бензофуран и индолтиазепинони, оксазепинони и диазепинони като инхибитори на клетъчна адхезия и на нiv
PA8542901A1 (es) Uso de (z)-2-ciano-3-hidroxi-but-2-acido enoico-(4-trifluorometilfenil)-amida para tratar la esclerosis multiple
EE200200565A (et) Vaskulaarse kahjustava toimega kombinatsioonravi
FR2438654A1 (fr) Compose de 2-methyl-dihydropyridine, procedes pour son obtention et composition pharmaceutique contenant ce compose
KR950702120A (ko) 골다공증 치료를 위한 포스포네이트의 용도(use of phosphonates for the treatment of osteoporosis)
AR018162A1 (es) Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
ES2194933T3 (es) Inhibidores de la agregacion plaquetaria.
FI934680A0 (fi) Arylmorfolin, framstaellning och anvaending
ES2159054T3 (es) Compuestos di-terc-butil-fenolicos que contienen azufre utiles como agentes antiinflamatorios.
ES2105923B1 (es) Composiciones para el tratamiento de una infeccion y una enfermedad causadas por el virus de la hepatitis b (hbv).
ES2086528T3 (es) Nuevos compuestos biciclicos sustituidos con amino.